KR20250011241A - Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체 - Google Patents

Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체 Download PDF

Info

Publication number
KR20250011241A
KR20250011241A KR1020257000876A KR20257000876A KR20250011241A KR 20250011241 A KR20250011241 A KR 20250011241A KR 1020257000876 A KR1020257000876 A KR 1020257000876A KR 20257000876 A KR20257000876 A KR 20257000876A KR 20250011241 A KR20250011241 A KR 20250011241A
Authority
KR
South Korea
Prior art keywords
ser
seq
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257000876A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 비. 웨이너
사라 엘리엇
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20250011241A publication Critical patent/KR20250011241A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020257000876A 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체 Pending KR20250011241A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
KR1020237013950A KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013950A Division KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Publications (1)

Publication Number Publication Date
KR20250011241A true KR20250011241A (ko) 2025-01-21

Family

ID=60203626

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257000876A Pending KR20250011241A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체
KR1020187035166A Ceased KR20190031439A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체
KR1020237013950A Ceased KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187035166A Ceased KR20190031439A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체
KR1020237013950A Ceased KR20230058733A (ko) 2016-05-05 2017-05-05 Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체

Country Status (12)

Country Link
US (1) US20190192692A1 (https=)
EP (1) EP3452106A4 (https=)
JP (3) JP7311113B2 (https=)
KR (3) KR20250011241A (https=)
CN (1) CN109789224A (https=)
AU (2) AU2017261292B2 (https=)
BR (1) BR112018072697A2 (https=)
CA (1) CA3023089A1 (https=)
EA (1) EA201892524A1 (https=)
MX (2) MX2018013523A (https=)
SG (2) SG11201809786TA (https=)
WO (1) WO2017192933A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
WO2022155404A1 (en) * 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
SI1960430T1 (sl) * 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
CN101563365B (zh) * 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Also Published As

Publication number Publication date
EP3452106A4 (en) 2020-01-08
JP2025147175A (ja) 2025-10-06
EA201892524A1 (ru) 2019-04-30
WO2017192933A1 (en) 2017-11-09
MX2025009846A (es) 2025-09-02
AU2017261292B2 (en) 2024-06-06
SG10202011023YA (en) 2020-12-30
CN109789224A (zh) 2019-05-21
KR20230058733A (ko) 2023-05-03
AU2017261292A1 (en) 2018-12-20
JP7311113B2 (ja) 2023-07-19
JP2019518074A (ja) 2019-06-27
JP2023086734A (ja) 2023-06-22
AU2024203109A1 (en) 2024-05-30
KR20190031439A (ko) 2019-03-26
US20190192692A1 (en) 2019-06-27
CA3023089A1 (en) 2017-11-09
EP3452106A1 (en) 2019-03-13
BR112018072697A2 (pt) 2019-02-19
MX2018013523A (es) 2019-06-10
SG11201809786TA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
AU2017261374B2 (en) DNA antibody constructs for use against pseudomonas aeruginosa
JP2025147175A (ja) Ｉｌ－６及びｃｄ１２６を標的とするｄｎａモノクローナル抗体
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
KR20240155978A (ko) 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
BR112019020235A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
JP2023126321A (ja) ライム病に対する使用のためのｄｎａ抗体構築物
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
CA3089717A1 (en) Nucleic acid antibody constructs for use against respiratory syncytial virus
US12617841B2 (en) Nucleic acid antibody constructs for use against respiratory syncytial virus
HK40013455A (en) Dna antibody constructs for use against lyme disease
WO2019152602A1 (en) Structurally modified flavivirus dmabs
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
US20210047388A1 (en) Nucleic acid antibody constructs for use against ebola virus
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
HK40009739A (en) Dna antibody constructs and method of using same
HK40009043A (zh) 靶向检查点分子的dna单克隆抗体

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250109

Application number text: 1020237013950

Filing date: 20230424

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250205

Comment text: Request for Examination of Application